Pavblu Injection, Solution
Product Images NDC 55513-065

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pavblu (NDC 55513-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pavblu 01)

This is a description of a syringe cap with a Luer Lock and a dosing line of 0.05 mL. It also features a plunger with a finger grip and a plunger rod.*

FDA Label Image

Figure 2 (Pavblu 02)

FDA Label Image

Figure 3 (Pavblu 03)

FDA Label Image

Figure 4 (Pavblu 04)

FDA Label Image

Figure 5a (Pavblu 05)

This text appears to be a list of components related to an air bubble dosing system, including a plunger, dome, and edge. This system may be used for dosing solutions through a line.*

FDA Label Image

Figure 5b (Pavblu 06)

This is not available.*

FDA Label Image

Figure 6 (Pavblu 07)

FDA Label Image

Figure 7 (Pavblu 08)

FDA Label Image

Figure 8a (Pavblu 09)

FDA Label Image

Figure 8b (Pavblu 10)

FDA Label Image

Figure 9a & 9b (Pavblu 11)

FDA Label Image

Figure 10a (Pavblu 12)

FDA Label Image

Figure 10b (Pavblu 13)

FDA Label Image

Figure 11 (Pavblu 14)

FDA Label Image

Figure 12a & 12b (Pavblu 15)

This text provides instructions for administering a dose of 0.05 mL using a syringe. It includes guidance on expelling air bubbles and excess drug from the solution before administering the medication. The text also references Figure 12a and Figure 12b, which likely show visual aids for proper administration techniques.*

FDA Label Image

Figure 13 (Pavblu 16)

This appears to be a chart showing the mean change in visual acuity over different weeks for different treatments such as Aflibercept and Ranibizumab. The chart lists the number of letters read, the weeks, and the dosages of the treatments. The data seems to compare visual acuity changes between Aflibercept injections every 8 weeks, Aflibercept injections every 4 weeks, and Ranibizumab injections every 4 weeks.*

FDA Label Image

Figure 14 (Pavblu 17)

Mean Change in Visual Acuity data from the COPERNICUS and GALILEO studies where patients were treated with Aflibercept 2 mg Q4 weeks compared to a control group. The visual acuity improvement after 20 weeks and 24 weeks is demonstrated in the study results.*

FDA Label Image

Figure 15 (Pavblu 18)

This text describes a comparison between two groups over a period of weeks, one being treated with Aflibercept 2 mg every 4 weeks, while the other group serves as the control. It indicates different timepoints and potentially outcomes being measured in the study.*

FDA Label Image

Figure 16 (Pavblu 19)

FDA Label Image

Figure 17 (Pavblu 20)

The text provides data about the proportion of patients at various time points during the study. It includes percentages such as 62.7%, 59.3%, 55.2%, 45.5%, 40.6%, 6.8%, 6.0%, 7.5%, 79.9%, 65.2%, 15.0%. The study mentions weeks 8, 12, 24, 40, and 52. Additionally, it appears to compare a control group (sham) with two groups receiving Aflibercept intervention in 2016 and 208.*

FDA Label Image

Principal Display Panel (0.05 mL Syringe Carton)

This description provides information about a medication called PAVBLU™, which comes in a prefilled syringe containing 2 mg of aflibercept-ayyh solution. The medication is not for sale and is intended for intravitreal injection. It includes details about the contents of the syringe and storage instructions, such as keeping it refrigerated and protecting it from light. Recommended dosage details are also mentioned, and it is advised to see the prescribing information for further guidance. Additionally, the text indicates that the product should be stored in its original carton and discarded if unused.*

FDA Label Image

Principal Display Panel (0.05 mL Vial Carton)

This is a description of a medication labeled with NDC 55513-065-01. It contains 2mg in 0.05 mL of a 40 mg/mL solution for Intravitreal Injection. It comes in a single-dose vial and is a sterile solution without antimicrobial preservatives. The label advises keeping it out of reach of children and discarding any unused portion. The text also includes the letter "R Only."*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.